A Case of Breast Cancer with Recurrent Peritoneal Dissemination Treated with Eribulin Mesilate

Abstract

We present the case of a patient with breast cancer suffering from intestinal obstruction due to peritoneal dissemination. With chemotherapy (eribulin mesylate), we were able to maintain her quality of life. The patient was a 50-year-old woman. At the age of 43, she received neoadjuvant chemotherapy (NAC) followed by breast-conserving tumor resection surgery and axillary dissection, followed by adjuvant radiation therapyadjuvant hormonal therapies. A mass at the operation site and bilateral axillary lymph node enlargement were found soon after the adjuvant hormonal treatment, and the hormone treatment was changed. However, the local mass and bilateral axillary lymph nodes only increased in size. At the same time, right upper limb numbness and restriction of movements from the fingers to forearm appeared. The hormone therapy was again changed to a CDK4/6 inhibitor and selective estrogen receptor downregulator, and an LHRH agonist as the second-line hormone therapy. However, an increase in the size of the locally recurrent tumor was noted in 6 months. The patient also developed nausea and vomiting at the same time. We diagnosed the condition as intestinal obstruction caused by peritoneal dissemination of breast cancer, and changed the hormonal treatment to chemotherapy (eribulin mesylate). After the end of one cycle, the patient could eat and the numbness of the upper limb disappeared.